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As part of the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveil-
lance program in 2012 the in vitro activity of ceftaroline and relevant comparator
antimicrobials was evaluated in six Latin American countries (Argentina, Brazil, Chile,
Colombia, Mexico and Venezuela) against pathogens isolated from patients with hospital
associated skin and soft tissue infections (SSTIs). The study documented that ceftaro-
line  was  highly active (MIC90 0.25 mg/L/% susceptible 100%) against methicillin-susceptible
Staphylococcus aureus, methicillin-resistant S. aureus (MIC90 2 mg/L/% susceptible 83.3%)
and -hemolytic streptococci (MIC90 0.008–0.015 mg/L/% susceptible 100%). The activity of
ceftaroline against selected species of Enterobacteriaceae was dependent upon the pres-
ence  or absence of extended-spectrum -lactamases (ESBLs). Against ESBL screen-negative
Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca the MIC90 and percent suscepti-
ble for ceftaroline were (0.5 mg/L/94.1%), (0.5 mg/L/99.0%) and (0.5 mg/L/91.5%), respectively.Ceftaroline demonstrated potent activity against a recent collection of pathogens associated
with SSTI in six Latin American countries in 2012.
© 2015 Elsevier Editora Ltda. All rights reserved.
appropriate antimicrobial regimens either empirical orIntroduction
Skin and soft tissue infections (SSTIs) cover a broad range
of infectious processes including wounds, abscesses, skin
structure, cellulitis, erysipelas, furuncles, burns, carbuncles,
impetigo, and a variety of animal bite infections.1 The
∗ Corresponding author at: International Health Management Associate
E-mail address: dbiedenbach@ihmainc.com (D. Biedenbach).
http://dx.doi.org/10.1016/j.bjid.2015.08.011
1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.successful management of both community-associated and
hospital associated SSTI involves accurate diagnosis, source
control, laboratory microbiological support, and as neededs Inc., 2122 Palmer Drive, Schaumburg, IL 60173, USA.
directed post culture and susceptibility testing.1–3
Irrespective of anatomical site, the bacterial etiology of SSTI
most frequently involves two species of Gram-positive cocci
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Table 1 – In vitro activity of ceftaroline against key
Gram-positive pathogens in SSTI from Latin America,
2012.
Organism Drug MIC90 %Sus.
Staphylococcus
aureus
(n = 696)
Ceftaroline 1 90.7
Oxacillin >2 44.0
Erythromycin >4 47.3
Clindamycin >2 76.0
Levoﬂoxacin >2 71.3
Moxiﬂoxacin >2 71.6
Minocycline 0.5 99.6
Tigecycline 0.5 100
Linezolid 2 100
Daptomycin 1 100
Vancomycin 1 100
Staphylococcus aureus
(MRSA)
(n = 390)
Ceftaroline 2 83.3
Oxacillin >2 0
Erythromycin >4 32.6
Clindamycin >2 57.7
Levoﬂoxacin >2 51.0
Moxiﬂoxacin >2 51.0
Minocycline 0.5 99.5
Tigecycline 0.5 100
Linezolid 2 100
Daptomycin 1 100
Vancomycin 1 100
Staphylococcus
aureus (MSSA)
(n = 306)
Ceftaroline 0.25 100
Oxacillin 1 100
Erythromycin >4 66.0
Clindamycin 0.12 99.4
Levoﬂoxacin 0.25 97.4
Moxiﬂoxacin 0.12 98.0
Minocycline 0.5 99.7
Tigecycline 0.5 100
Linezolid 2 100
Daptomycin 1 100
Vancomycin 1 100
Streptococcus
pyogenes
(n = 56)
Ceftaroline 0.008 100
Penicillin ≤0.015 100
Erythromycin 0.06 96.4
Clindamycin 0.03 96.4
Levoﬂoxacin 0.5 100
Tigecycline 0.06 100
Linezolid 1 100
Daptomycin 0.12 100
Vancomycin 1 100
Streptococcus
agalactiae
(n = 25)
Ceftaroline 0.015 100
Penicillin 0.12 100
Erythromycin >1 88.0
Clindamycin 0.5 84.0
Levoﬂoxacin 1 100
Tigecycline 0.06 100
Linezolid 1 100
Daptomycin 0.5 100
Vancomycin 1 100
Streptococcus
dysgalactiae
(n = 12)
Ceftaroline 0.008 100
Penicillin 0.03 100
Erythromycin 0.12 91.7
Clindamycin 0.06 100
Levoﬂoxacin 0.5 100
Tigecycline 0.25 100
Linezolid 1 100
Daptomycin 0.12 100
Vancomycin 0.25 100b r a z j i n f e c t d i s .
amely Staphylococcus aureus and -hemolytic streptococci as
ell as various members of the family Enterobacteriaceae and
seudomonas aeruginosa,  and rarely anaerobes.4–6
Surgical drainage/debridement as well as antimicrobial
herapy remains the mainstay of appropriate SSTI manage-
ent. However, increasing global antimicrobial resistance in
oth Gram-positive and Gram-negative pathogens including
hose associated with SSTI has complicated both empirical
nd directed antimicrobial therapy.1 Prevalence studies have
hown that over 50% of SSTI are caused by S. aureus including
ethicillin-resistant S. aureus (MRSA) thus greatly reducing
he inherent or preferred use of a -lactam for potential S.
ureus SSTI.7,8 The CDC considers MRSA a serious threat with
ver 80,000 severe MRSA infections per year and an unknown
ut much higher number of less severe infections including
STI.9
Over the past 15 years antimicrobials with activity against
RSA including vancomycin, daptomycin, tigecycline, and
inezolid have been available, but each of these has therapeutic
imitations and may not on their own provide cover-
ge of polymicrobial infections that include Gram-negative
athogens. In the face of increasing antimicrobial resistance
he search for new antimicrobials with activity against a
ariety of pathogens has led to the development and market-
ng of ceftaroline fosamil, a new broad-spectrum parenteral
ephalosporin. Ceftaroline, the active metabolite of ceftaro-
ine fosamil, inhibits penicillin-binding protein 2a of MRSA
nd shows effective activity against MRSA as well as against
ther Gram-positive cocci, and several species of Enterobac-
eriaceae (excluding those that produce extended-spectrum
-lactamases [ESBLs] or inducible AmpC -lactamases).10,11
rior in vitro susceptibility studies provide support of cef-
aroline activity against many  Gram-positive and commonly
solated Gram-negative pathogens.12–19
The AWARE (Assessing Worldwide Antimicrobial Resis-
ance Evaluation) global surveillance program was established
o monitor the susceptibility of pathogens to ceftaroline as
ell as relevant comparator antimicrobials to pathogens asso-
iated with SSTI as well as lower respiratory tract infection
athogens and complicated urinary tract infections in many
reas of the world including Latin America. This report sum-
arizes the data from SSTI pathogens from the AWARE
rogram in Latin America in 2012.
aterial  and  methods
acterial  isolates
 total of 1142 clinical isolates from patients with SSTI were
ollected from 17 medical centers in six Latin American
ountries in 2012: Argentina (three), Brazil (two), Chile (three),
olumbia (two), Mexico (ﬁve), and Venezuela (two). All isolates
ere collected from patients presenting with SSTI. The AWARE
urveillance program is not designed as a prevalence of infec-
ion study as each participating laboratory was asked to collect
nd submit a deﬁned number of speciﬁc pathogens from
STI (one isolate per patient infection episode). All isolates
ere submitted to International Health Management Asso-
iates Inc. (Schaumburg, IL, USA). Organism identiﬁcation was
CLSI susceptibilities deﬁned by CLSI document M100-S24 (2014),
where applicable; tigecycline susceptibilities under CLSI deﬁned by
FDA (2013).
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Table 2 – Frequency distribution of ceftaroline against Staphylococcus aureus and Streptococcus pyogenes in SSTI from Latin
America, 2012.
Organism Country n MIC (mg/L) (n/cumulative %)
≤0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2
S. aureus All  countries 696  3 56 248 231 93 65
0.4 8.5 44.1 77.3 90.7 100
Argentina 174 7 52 94 10 11
4 33.9 87.9 93.7 100
Brazil 20 4 10 4 2
20.0 70.0 90.0 100
Chile 126 1 16 44 17 3 45
0.8 13.5 48.4 61.9 64.3 100
Colombia 47 5 20 18 1 3
10.6 53.2 91.5 93.6 100
Mexico 189 1 16 71 25 76
0.5 9.0 46.6 59.8 100
Venezuela 140 1 8 51 73 3 4
0.7 6.4 42.9 95.0 97.1 100
MRSA All countries 390  8 224 93 65
20.1 59.5 83.3 100
Argentina 116 1 94 10 11
0.9 81.9 90.5 100
Brazil 6 4 2
66.7 100
Chile 63 1 14 3 45
1.6 23.8 28.6 100
Colombia 24 2 18 1 3
8.3 83.3 87.5 100
Mexico 100 2 22 76
2.0 24.0 100
Venezuela 81 2 72 3 4
2.5 91.4 95.1 100
MSSA All countries 306  3 56 240 7
1.0 19.3 97.7 100
Argentina 58 7 51
12.1 100
Brazil 14 4 10
28.6 100
Chile 63 1 16 43 3
1.6 27.0 95.2 100
Colombia 23 5 18
21.7 100
Mexico 89 1 16 69 3
1.1 19.1 96.6 100
Venezuela 59 1 8 49 1
1.7 15.3 98.3 100
S. pyogenes All countries 56  43 12 1
76.8 98.2 100
Argentina 14 9 4 1
64.3 92.9 100
Brazil 2 2
100
Chile 20 13 7
65.0 100
Mexico 12 11 1
91.7 100
Venezuela 8 8
100
conﬁrmed using a Bruker Biotyper MALDI-TOF instrument
(Bruker Daltonics, Billerica, MA,  USA).
Antimicrobial  susceptibility  testingMinimum inhibitory concentrations (MICs) were determined
by the broth microdilution method recommended by the
Clinical and Laboratory Standards Institute (CLSI)performance standard.20 Susceptibility was determined
according to interpretive criteria set by the CLSI or FDA as
appropriate.21,22 Breakpoints for ceftaroline have been rec-
ommended for S. aureus (≤1 mg/L, susceptible), streptococci,
and Enterobacteriaceae (≤0.5 mg/L, susceptible) by the CLSI.
All MIC panels were prepared at IHMA and frozen at −80 ◦C
prior to usage. MICs were entered into a central database
and only accepted if quality control values using appropriate
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Table 3 – In vitro activity of ceftaroline against key
Gram-negative pathogens in SSTI from Latin America,
2012.
Organism Drug MIC90 %Sus.
Citrobacter
freundii
(n = 14)
Ceftaroline 64 64.3
Ceftazidime 64 71.4
Cefepime 1 100
Aztreonam 32 78.6
Meropenem 0.06 100
Amoxicillin-
clavulanic
acid
>16 7.1
Piperacillin-
tazobactam
64 85.7
Levoﬂoxacin >4 78.6
Amikacin 16 92.9
Tigecycline 1 100
Citrobacter spp.
(n = 20)
Ceftaroline 16 75.0
Ceftazidime 32 80.0
Cefepime 0.25 100
Aztreonam 16 85.0
Meropenem 0.06 100
Amoxicillin-
clavulanic
acid
>16 35.0
Piperacillin-
tazobactam
16 90.0
Levoﬂoxacin >4 85.0
Amikacin 2 95.0
Tigecycline 1 100
Enterobacter
aerogenes
(n = 12)
Ceftaroline 32 83.3
Ceftazidime 32 83.3
Cefepime 4 91.7
Aztreonam 8 83.3
Meropenem 0.12 100
Amoxicillin-
clavulanic
acid
>16 0.0
Piperacillin-
tazobactam
64 83.3
Levoﬂoxacin 0.12 100
Amikacin 8 91.7
Tigecycline 1 100
Enterobacter
cloacae
(n = 24)
Ceftaroline >128 54.2
Ceftazidime 128 54.2
Cefepime >16 79.2
Aztreonam 128 58.3
Meropenem 0.25 100
Amoxicillin-
clavulanic
acid
>16 16.7
Piperacillin-
tazobactam
>128 62.5
Levoﬂoxacin >4 75.0
Amikacin 8 95.8
Tigecycline 2 95.8
Escherichia coli
(n = 86)
Ceftaroline >128 50.0
Ceftazidime 64 61.6
Cefepime >16 66.3
Aztreonam 128 59.3
Meropenem 0.03 98.8
Amoxicillin-
clavulanic
acid
16 54.7
Piperacillin-
tazobactam
64 83.7
Levoﬂoxacin >4 43.0
Table 3 (Continued)
Organism Drug MIC90 %Sus.
Amikacin 16 97.7
Tigecycline 1 100
Klebsiella
oxytoca
(n = 17)
Ceftaroline >128 76.5
Ceftazidime 4 94.1
Cefepime >16 82.4
Aztreonam 128 82.4
Meropenem 0.06 100
Amoxicillin-
clavulanic
acid
8 94.1
Piperacillin-
tazobactam
32 88.2
Levoﬂoxacin 1 100
Amikacin 8 100
Tigecycline 0.5 100
Klebsiella
pneumoniae
(n = 58)
Ceftaroline >128 46.6
Ceftazidime 128 46.6
Cefepime >16 60.3
Aztreonam >128 46.6
Meropenem 2 84.5
Amoxicillin-
clavulanic
acid
>16 51.7
Piperacillin-
tazobactam
>128 63.8
Levoﬂoxacin >4 65.5
Amikacin 32 89.7
Tigecycline 2 91.4
Morganella
morganii
(n = 14)
Ceftaroline 64 50.0
Ceftazidime 16 71.4
Cefepime 1 100
Aztreonam 2 100
Meropenem 0.25 100
Amoxicillin-
clavulanic
acid
>16 0.0
Piperacillin-
tazobactam
8 100
Levoﬂoxacin >4 35.7
Amikacin 2 100
Tigecycline 8 14.3
Proteus
mirabilis
(n = 32)
Ceftaroline >128 75.0
Ceftazidime 1 100
Cefepime >16 84.4
Aztreonam 2 90.6
Meropenem 0.12 100
Amoxicillin-
clavulanic
acid
16 81.3
Piperacillin-
tazobactam
2 100
Levoﬂoxacin >4 56.3
Amikacin 16 90.6
Tigecycline 4 37.5
CLSI susceptibilities deﬁned by CLSI document M100-S24 (2014),
where applicable; tigecycline susceptibilities under CLSI deﬁned by
FDA (2013).
American Type Culture Collection control strains were within
acceptable ranges. ESBL phenotypic activity was determined
by screening Escherichia coli,  Klebsiella pneumoniae, Klebsiella
oxytoca, and Proteus mirabilis with ceftazidime and aztreonam
according to CLSI guidelines.21 ESBL screen-positive was
deﬁned as any E. coli, K. pneumoniae, K. oxytoca, or P. mirabilis
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Table 4 – Frequency distribution (n) and cumulative percent inhibited (%) at each MIC  for ceftaroline against Escherichia coli and phenotypes in SSTI from Latin America,
2012.
Country Phenotype (n) MIC (mg/L) (n/cumulative %)
0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128
All countries
combined
All isolates (86) 9 16 14 3 1 3 2 1 3 3 1 4 26
10.5 29.1 45.3 48.8 50.0 53.0.5 55.8 57.0 60.5 64.0 65.1 69.8 100
ESBL screen-positive (38) 1 3 3 1 4 26
2.7 10.8 18.9 21.6 32.4 100
ESBL screen-negative (48) 9 16 14 3 1 3 2
18.8 52.1 81.2 87.5 89.6 95 100
Argentina All isolates (11) 1 5 2 1 1 1
9.1 54.5 72.7 81.8 90.9 100
ESBL screen-positive (2) 1  1
50.0 100
ESBL screen-negative (9) 1 5 2 1
11.1 66.7 88.9 100
Brazil All isolates (2) 1 1
50.0 100
ESBL screen positive (2) 1 1
50.0 100
Chile All isolates (8) 3 3 1 1
37.5 75.0 87.5 100
ESBL screen-positive (2) 1 1
50.0 100
ESBL screen-negative (6) 3 3
50.0 100
Colombia All isolates (8) 1 2 2 1 1 1
12.5 37.5 62.5 75.0 87.5 100
ESBL screen-positive (2) 1 1
50.0 100
ESBL screen-negative (6) 1 2 2 1
16.7 50.0 83.3 100
Mexico All isolates (42) 3 2 9 3 3 1 1 3 17
7.1 11.9 33.3 40.5 47.6 50.0 52.4 59.5 100
ESBL screen-positive (22) 1 1 3 17
4.5 9.1 22.7 100
ESBL screen-negative (20) 3 2 9 3 3
15.0 25.0 70.0 85.0 100
Venezuela All isolates (15) 1 4 1 1 1 7
6.7 33.3 40.0 46.7 53.3 100
ESBL screen-positive (7) 1 6
14.3 100
ESBL screen-negative (8) 1 4 1 1 1
12.5 62.5 75.0 87.5 100
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Table 5 – Frequency distribution (n) and cumulative percent inhibited (%) at each MIC  for ceftaroline against Klebsiella
pneumoniae and phenotypes in SSTI from Latin America, 2012.
Country Phenotype (n) MIC (mg/L) (n/cumulative %)
0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128
All countries
combined
All isolates (58) 14 6 5 2 1 1 6 23
24.1 34.5 43.1 47.0 48.0 50.0 60.0 100
ESBL screen-positive (31) 1 1 6 23
3.2 6.5 26.0 100
ESBL screen-negative (27) 14  6 5 2
51.9 74.1 92.6 100
Argentina All isolates (19) 3 1 2 13
15.8 21.1 31.6 100
ESBL screen-positive (13) 13
100
ESBL screen-negative (6) 3 1 2
50.0 66.7 100
Brazil All isolates (1) 1
100
ESBL screen-positive (1) 1
100
Chile All isolates (9) 1 1 1 6
11.1 22.2 33.0 100
ESBL screen-positive (7) 1 6
14.3 100
ESBL screen-negative (2) 1 1
50.0 100
Colombia All isolates (2) 1 1
50.0 100
ESBL screen-positive (2) 1 1
50.0 100
Mexico All isolates (20) 8 3 1 1 5 2
40.0 55.0 60.0 65.0 90.0 100
ESBL screen-positive (7) 5 2
71.4 100
ESBL screen-negative (13) 8 3 1 1
61.5 84.6 92.3 100
Venezuela All isolates (7) 2 1 2 1 1
28.6 42.9 71.4 86 100
ESBL screen-positive (1) 1
100
2 
83.3
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mESBL screen-negative (6) 2 1 
33.3 50.0 
solate with either ceftazidime or aztreonam MIC  values of
1 mg/L. All other E. coli,  K. pneumoniae, K. oxytoca, or P. mirabilis
solates were designated as ESBL screen-negative.
esults  and  discussion
n 2012 the 17 participating medical centers in Latin Amer-
ca contributed 1142 clinical isolates. The majority of isolates,
oth Gram-positive and Gram-negative, came from four main
nfection sources: wound (44%), abscess (26%), cellulitis (10%),
nd skin ulcers (9%). All other infection sites contributed ≤4%
f isolates.
The susceptibility of various Gram-positive cocci to cef-
aroline and relevant comparators is provided in Table 1.
gainst 696 S. aureus isolates (methicillin susceptible [MSSA]
nd MRSA isolates combined) the ceftaroline MIC90 was 1 mg/L
ith 90.7% of all isolates susceptible. Only tigecycline and
inocycline demonstrated lower MIC90 values of 0.5 mg/L.1
 100
S. aureus isolates irrespective of methicillin phenotype were
susceptible to daptomycin, linezolid, tigecycline, and van-
comycin. 100% of MSSA were susceptible to ceftaroline with
an MIC90 of 0.25 mg/L and 83.3% of MRSA susceptible to cef-
taroline with MIC90 of 2 mg/L. No MRSA were identiﬁed with
an MIC >2 mg/L (Table 1).
Variations in MIC90 for ceftaroline against MRSA were rel-
atively minor with ranges from 0.5 mg/L in isolates from
Venezuela to 2 mg/L in isolates from Brazil, Chile, and Colom-
bia. Ceftaroline MICs for MSSA isolates displayed minimal
variation (0.06–0.5 mg/L) with MIC90 of 0.25 mg/L irrespective
of country (Table 2). All -hemolytic streptococci (Strepto-
coccus agalactiae,  Streptococcus dysgalactiae, and Streptococcus
pyogenes) were susceptible to ceftaroline with MIC90 ranges
of 0.008–0.015 mg/L (Table 1) with 55/56 S. pyogenes ceftaro-
line MIC90 of ≤0.008 mg/L in all countries studied (Table 2).
Isolates were 100 percent susceptible to most comparators
with the exception of clindamycin and erythromycin where
susceptibility ranged from 84.0 to 96.4%.
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The activity of ceftaroline and comparators is shown
in Table 3 for relevant Gram-negative bacilli where n > 10.
MIC90/% susceptible for ceftaroline by species were: Cit-
robacter freundii (64/64.3%), Citrobacter spp. (16/75%), Entero-
bacter aerogenes (32/83.3%), Enterobacter cloacae (>128/54.2%),
E. coli (>128/50.0%), K. oxytoca (>128/76.5%), K. pneumo-
niae (>128/46.6%), Morganella morganii (64/50.0%), and Proteus
mirabilis (>128/75%). For most Gram-negative bacilli exam-
ined tigecycline, piperacillin-tazobactam, amikacin, and
meropenem displayed the highest percent susceptible ranging
from 91 to 100% susceptible with the exception of K. pneumo-
niae. The MIC  frequency distributions of ceftaroline against
both ESBL screen-positive and ESBL screen-negative E. coli, K.
pneumoniae, and K. oxytoca are shown in Tables 4–5. For all
six Latin American countries combined the ceftaroline MIC90
was >128 mg/L for all 86 E. coli with 50% of isolates suscep-
tible at the CLSI breakpoint of 0.5 mg/L (Table 4). Ceftaroline
was not active against ESBL screen-positive E. coli isolates with
all isolates demonstrating MICs ≥8 mg/L. However for ESBL
screen-negative isolates the MIC90 was 0.5 mg/L with 95% of
isolates susceptible. Two ESBL screen-negative E. coli isolates
(one each from Argentina and Colombia) were resistant to cef-
taroline with MICs of 2 mg/L. The MIC  frequency distribution of
ceftaroline against 58 K. pneumoniae from all Latin American
countries is shown in Table 5. MIC90 values were >128 mg/L
with only 48% of isolates susceptible at the CLSI breakpoint
of 0.5 mg/L. All 31 ESBL screen positive isolates were resis-
tant to ceftaroline, whereas all ESBL screen-negative isolates
were fully susceptible to ceftaroline. The MIC90 of ceftaroline
for all Latin American K. oxytoca isolates (17) was >128 mg/L
with 76.5% susceptible at 0.5 mg/L (data not shown). Only three
ESBL screen-positive isolates were identiﬁed from this region:
Chile (one) and Venezuela (two) with MIC  values of >128 mg/L.
For the ESBL screen-negative isolates the MIC90 was 0.5 mg/L
with only one isolate from Argentina for which the ceftaroline
MIC  was 4 mg/L.
All MSSA and all isolates of -hemolytic streptococci in this
study of SSTI major pathogens in Latin America were suscepti-
ble to ceftaroline (Table 1). This analysis conﬁrms prior reports
from Europe,15 Latin America,12,13 and the United States14 that
include MSSA isolates not only from SSTI but lower respi-
ratory tract infections. Of the MRSA isolates collected from
SSTI in Latin America 9.3% were identiﬁed as ceftaroline
intermediate (MIC 2 mg/L) and none of MRSA isolates were
ceftaroline resistant (MIC > 2 mg/L). The present study again
demonstrated that whereas ceftaroline resistance in MRSA
is uncommon geographical and regional variances can alter
the overall susceptibility of MRSA to ceftaroline.12,19 Ceftaro-
line exhibited potent activity against ESBL screen-negative
E. coli, K. pneumoniae and K. oxytoca in the present study as has
been previously shown in several surveillance studies in vari-
ous geographical areas.12–18 However ceftaroline had minimal
in vitro activity against ESBL screen-positive Enterobacteriaceae
SSTI isolates studied in this 2012 surveillance study in Latin
America. All surveillance studies have limitations including
isolate collection and data analysis. The AWARE surveillance
study is not a prevalence of infection study nor a direct
marker of phenotype prevalence as pathogen collection is
dictated by rigorous study protocols. However, organism iden-
tiﬁcation and susceptibility testing and interpretation are 1 5;1  9(6):596–603
rigorously followed with comprehensive quality control in
place.
In conclusion ceftaroline has been shown in this study and
in prior surveillance studies to exhibit potent activity against
MSSA and as a -lactam agent potent activity against MRSA
as well as -hemolytic streptococci and ESBL screen-negative
E. coli, K. pneumoniae, and K. oxytoca. SSTI currently represents
one of the most common community and hospital associated
infections globally and the need for new antimicrobials with
activity against the most common pathogens associated with
SSTI will need to continue to evolve. Ceftaroline represents
one such newer antimicrobial with documented in vitro activ-
ity against the critical SSTI pathogens tested in this study from
Latin America.
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